Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Clinical trial NCT06052852 · TERMINATED

Trial details

NCT number: NCT06052852
Sponsor: Bolt Biotherapeutics, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Clear Cell Renal Cell Carcinoma Ovarian Cancer Head and Neck Cancer Colorectal Cancer Non-small Cell Lung Cancer Melanoma

Start date: 2023-10-11
Primary completion: 2025-08-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.